imaGenes will provide service offerings with BioTrove’s OpenArray Platform, a nanoliter Real-Time qPCR, allowing for about 9,000 assays simultaneously.
Reportedly, OpenArray produces faster results, allowing gene expression profiling, microRNA profiling analyses and biomarker studies to be completed in lesser number of days and is cost effective. OpenArray technology utilises nanoliter fluidics enabling one person to generate over 27,000 assays per day.
The company claims that OpenArray offers six logs of sensi-tivity in a miniaturised customisable parallel array format with excellent correlation to data from conventional large volume Real-Time PCR.
Derek Potter, director for Europe at BioTrove, said: “We chose imaGenes for their extensive experience in microarray and next generation sequencing services. A spirited company with a well established quality management is an ideal partner to convince customers of the benefits of BioTrove’s OpenArray platform.”